Biography and Research Information
OverviewAI-generated summary
Fengping Lv's research focuses on the design, synthesis, and biological evaluation of novel chemical compounds. This work includes the discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors, as detailed in a 2021 publication. Lv also investigates biological processes at the molecular level, including research on ubiquitination-mediated degradation of TRDMT1 and its regulation of homologous recombination and therapeutic response, also published in 2021. Lv has a h-index of 12, with 28 total publications and 811 citations. Collaborations include work with Brendan Frett at the University of Arkansas for Medical Sciences, with whom Lv shares one publication.
Metrics
- h-index: 12
- Publications: 28
- Citations: 814
Selected Publications
-
Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response (2021)
-
Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation (2021)
Collaboration Network
Top Collaborators
Wei Yan
University of Arkansas for Medical Sciences (US)
2 shared publications
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
- Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Hongyu Li
University of Arkansas for Medical Sciences (US)
2 shared publications
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
- Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Lingtian Zhang
University of Arkansas for Medical Sciences (US)
1 shared publication
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
Marialuisa Moccia
University of Naples Federico II (IT)
1 shared publication
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
Francesca Carlomagno
Institute for Experimental Endocrinology and Oncology (IT)
1 shared publication
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
Christophe Landry
Université d'Artois (FR)
1 shared publication
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
Massimo Santoro
University of Naples Federico II (IT)
1 shared publication
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
Fabien Gosselet
Université d'Artois (FR)
1 shared publication
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
Brendan Frett
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation
Xiaolan Zhu
Harvard University (US)
1 shared publication
- Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Xiangyu Wang
Massachusetts General Hospital (US)
1 shared publication
- Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Haibo Yang
Massachusetts General Hospital (US)
1 shared publication
- Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Yufei Xiang
University of Pittsburgh (US)
1 shared publication
- Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Yi Shi
University of Pittsburgh (US)
1 shared publication
- Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Li Lan
Harvard University (US)
1 shared publication
- Ubiquitination-mediated degradation of TRDMT1 regulates homologous recombination and therapeutic response
Similar Researchers
Based on overlapping research topics
Phuc Tran
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Baha’a Jabali
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Gunaganti Naresh
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Maha Hanafi
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Protein Degradation and Inhibitors
Darin E. Jones
University of Arkansas for Medical Sciences
Computational Drug Discovery Methods
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Rick D. Edmondson
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Molecular Biology Techniques and Applications
Protein Degradation and Inhibitors